Analysts Issue Forecasts for VYGR FY2029 Earnings

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Analysts at Wedbush issued their FY2029 earnings per share (EPS) estimates for shares of Voyager Therapeutics in a research note issued to investors on Tuesday, February 11th. Wedbush analyst Y. Zhong anticipates that the company will post earnings of ($0.86) per share for the year. Wedbush has a “Outperform” rating and a $9.00 price target on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($0.91) per share.

Several other brokerages also recently issued reports on VYGR. Leerink Partnrs upgraded Voyager Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 16th. Citigroup started coverage on Voyager Therapeutics in a research report on Monday, December 2nd. They set a “buy” rating and a $12.00 price target for the company. StockNews.com cut shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Voyager Therapeutics in a report on Thursday, November 14th. Finally, Leerink Partners started coverage on shares of Voyager Therapeutics in a research note on Wednesday, October 16th. They set an “outperform” rating and a $15.00 target price on the stock. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $15.72.

Voyager Therapeutics Stock Up 0.5 %

Voyager Therapeutics stock opened at $4.44 on Thursday. Voyager Therapeutics has a 52-week low of $4.00 and a 52-week high of $10.66. The firm has a market capitalization of $242.56 million, a price-to-earnings ratio of 6.28 and a beta of 0.91. The firm has a 50-day moving average price of $5.65 and a two-hundred day moving average price of $6.32.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.29. The business had revenue of $24.63 million during the quarter, compared to analyst estimates of $12.63 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same quarter in the prior year, the firm earned ($0.59) earnings per share.

Insider Activity

In other Voyager Therapeutics news, COO Robin Swartz sold 6,500 shares of Voyager Therapeutics stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $5.65, for a total value of $36,725.00. Following the completion of the sale, the chief operating officer now directly owns 112,328 shares in the company, valued at $634,653.20. The trade was a 5.47 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold a total of 10,778 shares of company stock worth $58,548 in the last ninety days. Corporate insiders own 4.53% of the company’s stock.

Hedge Funds Weigh In On Voyager Therapeutics

Hedge funds have recently bought and sold shares of the business. Dynamic Technology Lab Private Ltd acquired a new position in shares of Voyager Therapeutics during the 4th quarter valued at about $267,000. Wells Fargo & Company MN raised its position in shares of Voyager Therapeutics by 3.7% in the fourth quarter. Wells Fargo & Company MN now owns 66,718 shares of the company’s stock valued at $378,000 after purchasing an additional 2,400 shares during the period. ExodusPoint Capital Management LP boosted its holdings in Voyager Therapeutics by 99.5% during the fourth quarter. ExodusPoint Capital Management LP now owns 65,830 shares of the company’s stock valued at $373,000 after acquiring an additional 32,834 shares during the period. Massachusetts Financial Services Co. MA lifted its position in shares of Voyager Therapeutics by 8.2% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 186,000 shares of the company’s stock worth $1,055,000 after purchasing an additional 14,144 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in Voyager Therapeutics by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 1,084,238 shares of the company’s stock valued at $6,149,000 after buying an additional 4,729 shares during the last quarter. 48.03% of the stock is owned by institutional investors and hedge funds.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.